The FDA has authorized a new medicine named Lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis. Demodex blepharitis affects around 25 million individuals in the United States and produces symptoms such as redness, inflammation of the eyelids, loss of eyelashes, and itching of the eyelids. The active component, lotilaner, kills the Demodex mites that infiltrate the lash follicles and create the disease. Treatment with lotilaner twice daily for 6 weeks resulted in considerably greater cure rates than placebo in two clinical studies involving over 800 patients. The medicine reduced collarettes—an indication of Demodex blepharitis—to two or less per eyelid in more than half of the patients, compared to roughly 15% for placebo. The drug also increased mite eradication rates and reduced eyelid inflammation.

To know more: About the original article click here.